FRAX¹¤¾ßÓ¦ÓöÔÀÏÄêÈ˹ÇÖÊÊèËÉÐÔ¹ÇÕÛ·çÏÕµÄÔ¤²â¼°ÒâÒå
Ä¿µÄ£ºÌ½ÌÖÓ¦ÓÃFRAX¹¤¾ßÔ¤²âÀÏÄêÈ˹ÇÖÊÊèËÉÐÔ¹ÇÕ۵ķçÏÕ²¢½øÐиÉÔ¤µÄÒâÒå¡£·½·¨£ºÑ¡È¡186ÃûÀÏÄêÈË£¬·ÖΪÄÐÅ®Á½×飬ÊÕ¼¯ÕûÀíÉí¸ß¡¢ÌåÖØ¡¢ÎüÑÌÒû¾ÆÊ·¡¢¼ÈÍù¹ÇÕÛÊ·¡¢¼¤ËØʹÓÃÊ·µÈÊý¾Ý£¬µÇ½»¥ÁªÍøͨ¹ýFRAX¹¤¾ß¼ì²âÕß10ÄêÄÚ·¢Éú¹ÇÖÊÊèËÉÐÔ¹ÇÕ۵ĸÅÂÊ¡£¶ÔÔ¤²â³öµÄ¹ÇÕÛ·çÏÕ¸ßÕß½øÐн¡¿µ½ÌÓý£¬±ØҪʱʵʩҩÎïÖÎÁÆ£¬½øÐиÉÔ¤ÒÔÆÚ¼õÉÙ¹ÇÕÛ·¢Éú¡£½á¹û£ºFRAXÈí¼þ¼ÆËã·ÖÎö³ö×ÜÈËȺδÀ´10ÄêÄÚÖ÷Òª²¿Î»´àÐÔ¹ÇÕÛ·çÏÕºÍ÷Ų¿´àÐÔ¹ÇÕÛ¸ÅÂÊ·Ö±ðΪ£¨1.48¡À0.24£©%¡¢£¨2.71¡À1.52£©%£¬·çÏսϸߡ£¶øÔÚ·Ö×éÉÏÅ®ÐÔ¹ÇÕÛ·çÏÕÃ÷ÏÔ´óÓÚÄÐÐÔ£¬±È½Ï²îÒìÓÐͳ¼ÆѧÒâÒ壨P£¼0.05£©¡£½áÂÛ£ºÓ¦ÓÃFRAX¹¤¾ß¿ªÕ¹¹ÇÕÛ·çÏÕÆÀ¹ÀÔ¤·À¹ÇÖÊÊèËÉÐÔ¹ÇÕÛÓлý¼«ÒâÒ壬¶øÇÒ¼òµ¥·½±ã¡¢¼Û¸ñµÍÁ®£¬¾ßÓÐÒ»¶¨µÄÉç»á¼°¾¼ÃЧÒ棬ֵµÃÍƹ㡣
±êÇ©£º ¹ÇÖÊÊèËÉ£» ¹ÇÕÛ£» FRAX£» ÁÙ´²ÒâÒå
¹ÇÖÊÊèËÉÐÔ¹ÇÕÛÓֳƴàÐÔ¹ÇÕÛ£¬ÊǹÇÖÊÊèËÉÖ¢×î³£¼ûµÄÑÏÖز¢·¢Ö¢£¬Êǵ¼ÖÂÀÏÄêÈËËÀÍö»ò²Ð¼²µÄÖØÒªÒòËØ[1]¡£¹ÇÕ۵ķçÏÕËæÄêÁäÔö¼Ó¶øÔö¼Ó£¬Èç¹ûͨ¹ýÊʵ±µÄ¹¤¾ßÄÜÔçÆÚ¶Ô¿ÉÄÜ·¢Éú¹ÇÕÛµÄÀÏÄêÈ˽øÐÐÓÐЧɸ²éºÍʶ±ð£¬´Ó¶ø¾¡Ôç½øÐÐÓÐЧ¸ÉÔ¤ºÍÖÎÁÆ£¬ÔöÇ¿¹ÇÃܶȣ¬Ô¤·À»ò½µµÍ¹ÇÕÛË𺦣¬Ôò¶ÔÌá¸ßÀÏÄêÈ˵ÄÉú»îÖÊÁ¿ºÍÊÙÃü½«Æðµ½»ý¼«µÄÒâÒå¡£FRAX£¨Fracture risk assessment tool£©¹¤¾ßÊǽü¼¸ÄêÀ´WHOÍƼöʹÓõĹÇÕÛ·çÏÕÒò×Ó¹¤¾ß£¬¿Éµ¥¶ÀʹÓÃÀ´Õï¶ÏºÍÆÀ¹À»¼ÕßδÀ´10Äê¹ÇÕ۵ĿÉÄÜÐÔ¡£±¾Ñо¿ÀûÓÃFRAX¹¤¾ß½áºÏ¶à¸öΣÏÕÒò×Ó¶Ôij¸ÉÐÝËù186ÃûÀÏÄêÈËȺ½øÐÐÔ¤²â£¬²¢¶Ô½á¹û½øÐзֲãɸ²é¿ÉÒɹÇÕÛ»¼Õߣ¬´Ó¶ø¶ÔÁÙ´²ÔçÆÚÕï¶Ï¡¢Ô¤·ÀºÍÖÎÁÆÌṩ¶à·½Ãæ²Î¿¼ÒÀ¾ÝºÍ½¨Òé¡£
1 ×ÊÁÏÓë·½·¨
1.1 Ò»°ã×ÊÁÏ
×Ô2012Äê10ÔÂÆð£¬ÏȺó¹²Ñ¡È¡186ÃûÀÏÄêÈËÈë×é½øÐÐɸѡ¸ÉÔ¤¡£ÆäÖÐÄÐ132Ãû£¬Å®54Ãû¡£¾ùÅųý¶à·¢ÐÔ¹ÇËèÁö¡¢¼×ÅÔ¿º¡¢¹ÇתÒÆÁöµÈÃ÷ÏÔÓ°Ïì¹Ç´úлµÄ¼²²¡¼°¸ÎÉö¼²²¡µÈ¡£ÊÕ¼¯ÕûÀíÉí¸ß¡¢ÌåÖØ¡¢¼ÈÍù¹ÇÕÛÊ·¡¢ÎüÑÌÒû¾ÆÊ·¡¢¼¤ËØʹÓÃÊ·µÈÊý¾Ý£¬ÒÔÓÃÓÚ½øÐзÖÎö¡£
1.2 Ñо¿·½·¨
FRAXÈí¼þ·ÖÎö£ºµÇ½http£º//www.sheffield.ac.uk/FRAX/ÍøÕ¾£¬ÔÚ¡°Country¡±ÏîÑ¡Ôñ¡°China¡±£¬¸ù¾Ý½çÃæÌáʾÒÀ´ÎÊäÈëÄêÁä¡¢ÐÔ±ð¡¢Éí¸ß¡¢ÌåÖØ¡¢¼ÈÍù¹ÇÕÛÊ·¡¢Ä¿Ç°ÎüÑÌÇé¿ö¡¢¸¸Ä¸÷Ų¿¹ÇÕÛ¡¢ÉöÉÏÏÙƤÖʼ¤ËØʹÓᢷçʪÐԹؽÚÑס¢¼Ì·¢ÐÔ¹ÇÖÊÊèËÉÖ¢¡¢Ã¿Èվƾ«ÉãÈ¡Á¿´ï3¸öµ¥Î»¼°ÒÔÉϵÈ11ÏîÊý¾Ý×ÊÁÏ£¬Èí¼þ×Ô¶¯¼ÆËã³öÊܼìÕß10ÄêÄÚÖ÷Òª²¿Î»·¢Éú¹ÇÖÊÊèËÉÐÔ¹ÇÕÛ£¨MO£©ºÍ10ÄêÄÚ·¢Éú÷Ų¿¹ÇÖÊÊèËÉÐÔ¹ÇÕÛ£¨HF£©µÄ¸ÅÂÊ¡£
1.3 ͳ¼Æѧ´¦Àí
²ÉÓÃSPSS 13.0Èí¼þ¶ÔËùµÃÊý¾Ý½øÐÐͳ¼Æ·ÖÎö£¬¼ÆÁ¿×ÊÁÏÓþùÊý¡À±ê×¼²î£¨x¡Às£©±íʾ£¬±È½Ï²ÉÓÃt¼ìÑ飬¼ÆÊý×ÊÁϲÉÓÃ×Ö2¼ìÑ飬P£¼0.05Ϊ²îÒìÓÐͳ¼ÆѧÒâÒå¡£
2 ½á¹û
2.1 FRAXÈí¼þÔ¤²â×ÜÈËȺ¹ÇÕ۵ķçÏÕ¸ÅÂÊ
186ÃûÊܲâÈËȺÄêÁä58¡«83Ë꣬ƽ¾ù£¨72.6¡À10.2£©Ë꣬
FRAXÈí¼þ¼ÆËã·ÖÎöδÀ´10ÄêÄÚÖ÷Òª²¿Î»´àÐÔ¹ÇÕÛ·çÏÕºÍ÷Ų¿´àÐÔ¹ÇÕÛ¸ÅÂÊ·Ö±ðΪ£¨1.48¡À0.24£©%¡¢£¨2.71¡À1.52£©%£¬·çÏսϸߡ£
2.2 FRAXÈí¼þÔ¤²â²»Í¬ÐÔ±ðÈËȺ¹ÇÕ۵ķçÏÕ¸ÅÂÊ
½«ÊܲâÈËȺ°´ÄÐÐÔ¡¢Å®ÐÔ·Ö×éͳ¼Æ£¬ÄÐÐÔ¡¢Å®ÐÔµÄÄêÁä¡¢ÌåÖØÖ¸Êý±È½Ï²îÒì¾ùÎÞͳ¼ÆѧÒâÒ壨P>0.05£©¡£¶øÔÚÖ÷Òª²¿Î»´àÐÔ¹ÇÕÛ·çÏÕºÍ÷Ų¿´àÐÔ¹ÇÕÛ·çÏÕ·½ÃæÅ®ÐÔ¾ùÃ÷ÏÔ´óÓÚÄÐÐÔ£¬±È½Ï²îÒì¾ùÓÐͳ¼ÆѧÒâÒ壨P>0.05£©£¬Ïê¼û±í1¡£
3 ÌÖÂÛ
¹ÇÖÊÊèËÉÐÔ¹ÇÕÛÓֳƴàÐÔ¹ÇÕÛ£¬Ö¸Ô·¢ÐÔ¹ÇÖÊÊèËÉÖ¢µ¼Ö¹ÇÃܶȺ͹ÇÖÊÁ¿Ï½µ£¬¹ÇÇ¿¶È¼õµÍ£¬ÔÚÈÕ³£»î¶¯ÖÐÊܵ½Çá΢±©Á¦¼´¿É·¢ÉúµÄ¹ÇÕÛ£¬ÊǹÇÖÊÊèËÉÖ¢×îÑÏÖصĺó¹û[2]¡£¹ÇÕÛ·¢Éúºóµ¼Ö»¼Õß²¡²ÐÂʺÍËÀÍöÂÊÃ÷ÏÔÔö¼Ó£¬¸ø»¼Õß¼ÒÍ¥¼°Éç»á´øÀ´ÁËÑÏÖصĸºµ£[3]¡£Òò´Ë½øÐйÇÕÛ·çÏÕÆÀ¹ÀÔ¤·À¹ÇÖÊÊèËÉÐÔ¹ÇÕ۵ķ¢ÉúÒѳÉΪȫÊÀ½ç¹Ø×¢µÄ½¡¿µÎÊÌâ[4]¡£
¶øË«ÄÜXÏß¹ÇÃܶȼì²âÒDZȽϰº¹ó£¬·ÑÓýϸߣ¬ÁÙ´²Ó¦ÓÃÉÐδÆÕ¼°£¬Òò´ËÔÚ²»ÄÜ»ò²»·½±ã¼ì²â¹ÇÃܶȵĵط½£¬µ¥µ¥ÀûÓÃÏà¹ØΣÏÕÒò×Ó½øÐÐFRAX Èí¼þ¼ÆËã¼´¿ÉÒԶԸõØÇøÈËȺµÄ¹ÇÕÛ·çÏÕ¸ÅÂʽøÐнÏΪ׼ȷµÄÔ¤²âºÍÆÀ¹À[5]¡£2011ÄêÎÒ¹úÖлªÒ½Ñ§»á¹ÇÖÊÊèËɺ͹ǿóÑμ²²¡·Ö»áÖ¸¶¨µÄ¡¶Ô·¢ÐÔ¹ÇÖÊÊèËÉÕïÁÆÖ¸ÄÏ¡·ÖÐÒ²ÍƼöʹÓÃFRAXÀ´ÆÀ¹À¹ÇÕÛ·çÏÕ²¢¸ÉÔ¤ÖÎÁÆ¡£ÓйØÑо¿±íÃ÷£¬ÀûÓÃFRAX¹¤¾ßÆÀ¹À³ö¹ÇÕÛ¸ßΣÈËȺ£¬ÔçÆÚʹÓÃÒ©Îï½øÐиÉÔ¤ÖÎÁƾßÓÐÁÆЧÏÔÖøµÄÌصã[6]¡£
ÖµµÃÇ¿µ÷µÄÊǹÇÖÊÊèËÉÐÔ¹ÇÕÛÊÇ¿É·À¡¢¿ÉÖεģ¬¾¡ÔçÔ¤·À¿ÉÒÔ±ÜÃâ¹ÇÖÊÊèËÉÒÔ¼°¹ÇÕÛ¡£±ÊÕ߶Լì³öµÄ¹ÇÕÛ¸ßΣÈËȺ½øÐÐÁ˽¡¿µ½ÌÓý£¬Òª³ä·ÖÌá¸ßÈÏʶ£¬ÇÐʵ×öºÃ°²È«·À»¤£¬°üÀ¨µ÷ÕûÉú»î·½Ê½£¬½ûÑÌÏ޾ƣ¬¶àʳ¸ß¸Æ¡¢µÍÑκÍÊÊÁ¿µ°°×ÖʵÄʳÎÊʵ±Ôö¼Ó»§Íâ»î¶¯ºÍ¹âÕÕʱ¼ä£¬²ÉÈ¡·ÀÖ¹µøµ¹µÄ·½Ê½£¬¿ÉʹÓùÕÕÈ¡¢ÂÖÒεÈÖúÐУ¬¾Ó¼Ò»·¾³¸ÄÔ죬·½±ãÀÏÈËÐж¯µÈ[7]¡£¶ø¶ÔÌرðÑÏÖØÕß½¨Òéµ½Éϼ¶Ò½Ôº½øÒ»²½ÕïÁÆ£¬²ÉÈ¡Á˲¹³ä¸Æ¼Á¡¢Î¬ÉúËØD¼°·þÓÃË«Á×ËáÑΡ¢öÙÓã½µ¸ÆËصȿ¹¹ÇÖÊÊèËÉÒ©ÎïµÄ¸ÉÔ¤£¬ÊÕµ½ÁËÓëÎéÏÈÃ÷µÈ[8]Ñо¿½üËƵÄЧ¹û¡£
×ÛÉÏËùÊö£¬Ó¦ÓÃFRAX¹¤¾ß¿ªÕ¹¹ÇÕÛ·çÏÕÆÀ¹ÀÔ¤·À¹ÇÖÊÊèËÉÐÔ¹ÇÕÛÓлý¼«ÒâÒ壬¶øÇÒ¼òµ¥·½±ã¡¢¼Û¸ñµÍÁ®£¬¾ßÓÐÒ»¶¨µÄÉç»á¼°¾¼ÃЧÒ棬ֵµÃÍƹ㡣
²Î¿¼ÎÄÏ×
[1]Ò¶Ô¶»Ô.¹ÇÖÊÊèËɹÇÕÛºóÔÙ¹ÇÕÛÁÙ´²·çÏÕ·ÖÎö[J].ÖÐÍâҽѧÑо¿£¬2013£¬11£¨3£©£º128.
[2] Meng X W£¬Xu L.Osteoporosis and bone mineral disease treatment guidelines[J].Chinese Journal of Osteoporosis and Bone Mineral Research£¬2006£¬12£¨5£©£º156.
[3]¹ù½¨Ãñ.ÀÏÄêÈË÷Ų¿¹ÇÖÊÊèËÉÐÔ¹ÇÕÛÑо¿½øÕ¹[J].Öйúҽѧ´´Ð£¬2014£¬11£¨9£©£º134-136.
[4] Melton L J.Adverse outcomes of osteoporotic fractures in the general population[J].J Bone Miner Res£¬2003£¬18£¨5£©£º1139-1141.
[5]Ðí꿵¤£¬°üÀö»ª£¬³ÌÐñ£¬µÈ.FRAXÆÀ¹ÀÄϾ©µØÇøÖÐÀÏÄêÈËȺ¹ÇÕÛ·çÏÕµÄÁÙ´²Ñо¿[J].Öйú¹ÇÖÊÊèËÉÔÓÖ¾£¬2014£¬9£¨20£©£º1112-1116.
[6] McCloskey E V£¬Johansson H£¬Oden A£¬et al.FRAX and the assessement of fracture probability identifies women who will benefit from clodronate therapy-additional results from a double blind£¬placeocontrolled randomized study[J].Osteoporos Int£¬2009£¬20£¨6£©£º811-817.
[7]ÀîËØÒÕ.ÀÏÄê¹ÇÖÊÊèËÉÖ¢ÁÙ´²»¤Àí¸ÉԤЧ¹û·ÖÎö[J].ÖÐÍâҽѧÑо¿£¬2013£¬11£¨12£©£º74-75.
[8]ÎéÏÈÃ÷£¬Îâ¿¡.öÙÓã½µ¸ÆËØ£¨ÃܸÇÏ¢£©ÖÎÁÆÀÏÄê¹ÇÖÊÊèËÉÖ¢µÄÁÆЧ·ÖÎö[J].Öйúҽѧ´´Ð£¬2013£¬10£¨4£©£º4-6.
FRAX¹¤¾ßÓ¦ÓöÔÀÏÄêÈ˹ÇÖÊÊèËÉÐÔ¹ÇÕÛ·çÏÕµÄÔ¤²â¼°ÒâÒå



